GB0810902D0 - New compounds - Google Patents

New compounds

Info

Publication number
GB0810902D0
GB0810902D0 GBGB0810902.7A GB0810902A GB0810902D0 GB 0810902 D0 GB0810902 D0 GB 0810902D0 GB 0810902 A GB0810902 A GB 0810902A GB 0810902 D0 GB0810902 D0 GB 0810902D0
Authority
GB
United Kingdom
Prior art keywords
new compounds
compounds
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0810902.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astex Therapeutics Ltd
Original Assignee
Astex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astex Therapeutics Ltd filed Critical Astex Therapeutics Ltd
Priority to GBGB0810902.7A priority Critical patent/GB0810902D0/en
Publication of GB0810902D0 publication Critical patent/GB0810902D0/en
Priority to CN200980122215.8A priority patent/CN102137859B/zh
Priority to US12/997,754 priority patent/US8796244B2/en
Priority to BRPI0915084A priority patent/BRPI0915084B8/pt
Priority to LTEP09761801.1T priority patent/LT2300465T/lt
Priority to HUE09761801A priority patent/HUE045300T2/hu
Priority to SI200931974T priority patent/SI2300465T1/sl
Priority to JP2011512999A priority patent/JP5596023B2/ja
Priority to DK09761801.1T priority patent/DK2300465T3/da
Priority to KR1020117000791A priority patent/KR101745730B1/ko
Priority to NZ589781A priority patent/NZ589781A/xx
Priority to EP09761801.1A priority patent/EP2300465B1/en
Priority to CA2727062A priority patent/CA2727062A1/en
Priority to HRP20191027 priority patent/HRP20191027T1/hr
Priority to AU2009256584A priority patent/AU2009256584B2/en
Priority to ES09761801T priority patent/ES2735979T3/es
Priority to RU2011100786/04A priority patent/RU2518089C2/ru
Priority to PCT/EP2009/057318 priority patent/WO2009150240A1/en
Priority to MX2010013743A priority patent/MX2010013743A/es
Priority to IL209864A priority patent/IL209864A/en
Priority to ZA2010/08961A priority patent/ZA201008961B/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
GBGB0810902.7A 2008-06-13 2008-06-13 New compounds Ceased GB0810902D0 (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
GBGB0810902.7A GB0810902D0 (en) 2008-06-13 2008-06-13 New compounds
MX2010013743A MX2010013743A (es) 2008-06-13 2009-06-12 Derivados de imidazopiridina como inhibidores de receptor de tirosina-cinasas.
NZ589781A NZ589781A (en) 2008-06-13 2009-06-12 Imidazopyridine derivatives as inhibitors of receptor tyrosine kinases
CA2727062A CA2727062A1 (en) 2008-06-13 2009-06-12 Imidazopyridine derivatives as inhibitors of receptor tyrosine kinases
BRPI0915084A BRPI0915084B8 (pt) 2008-06-13 2009-06-12 composto, e, composição farmacêutica
LTEP09761801.1T LT2300465T (lt) 2008-06-13 2009-06-12 Imidazopiridino dariniai kaip receptoriaus tirozino kinazių inhibitoriai
HUE09761801A HUE045300T2 (hu) 2008-06-13 2009-06-12 Imidazopiridin származékok, mint receptor tirozin kinázok inhibitorai
SI200931974T SI2300465T1 (sl) 2008-06-13 2009-06-12 Imidazopiridinski derivati kot inhibitorji receptorskih tirozin kinaz
JP2011512999A JP5596023B2 (ja) 2008-06-13 2009-06-12 レセプターチロシンキナーゼのインヒビターとしてのイミダゾピリジン誘導体
DK09761801.1T DK2300465T3 (da) 2008-06-13 2009-06-12 Imidazopyridinderivater som hæmmere af receptortyrosinkinaser
KR1020117000791A KR101745730B1 (ko) 2008-06-13 2009-06-12 수용체 티로신 키나제의 억제제로서의 이미다조피리딘 유도체
CN200980122215.8A CN102137859B (zh) 2008-06-13 2009-06-12 作为受体酪氨酸激酶的抑制剂的咪唑并吡啶衍生物
EP09761801.1A EP2300465B1 (en) 2008-06-13 2009-06-12 Imidazopyridine derivatives as inhibitors of receptor tyrosine kinases
US12/997,754 US8796244B2 (en) 2008-06-13 2009-06-12 Imidazopyridine derivatives as inhibitors of receptor tyrosine kinases
HRP20191027 HRP20191027T1 (hr) 2008-06-13 2009-06-12 Derivati imidazopiridina kao inhibitori tiposinskih receptora kinaza
AU2009256584A AU2009256584B2 (en) 2008-06-13 2009-06-12 Imidazopyridine derivatives as inhibitors of receptor tyrosine kinases
ES09761801T ES2735979T3 (es) 2008-06-13 2009-06-12 Derivados de la imidazopiridina como inhibidores de tirosina quinasas receptoras
RU2011100786/04A RU2518089C2 (ru) 2008-06-13 2009-06-12 Производные имидазопиридина в качестве ингибиторов рецепторных тирозинкиназ
PCT/EP2009/057318 WO2009150240A1 (en) 2008-06-13 2009-06-12 Imidazopyridine derivatives as inhibitors of receptor tyrosine kinases
IL209864A IL209864A (en) 2008-06-13 2010-12-09 History of imidazopyridine as tyrosine receptor kinase inhibitors
ZA2010/08961A ZA201008961B (en) 2008-06-13 2010-12-13 Imidazopyridine derivatives as inhibitors of receptor tyrosine kinases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0810902.7A GB0810902D0 (en) 2008-06-13 2008-06-13 New compounds

Publications (1)

Publication Number Publication Date
GB0810902D0 true GB0810902D0 (en) 2008-07-23

Family

ID=39672279

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0810902.7A Ceased GB0810902D0 (en) 2008-06-13 2008-06-13 New compounds

Country Status (21)

Country Link
US (1) US8796244B2 (enExample)
EP (1) EP2300465B1 (enExample)
JP (1) JP5596023B2 (enExample)
KR (1) KR101745730B1 (enExample)
CN (1) CN102137859B (enExample)
AU (1) AU2009256584B2 (enExample)
BR (1) BRPI0915084B8 (enExample)
CA (1) CA2727062A1 (enExample)
DK (1) DK2300465T3 (enExample)
ES (1) ES2735979T3 (enExample)
GB (1) GB0810902D0 (enExample)
HR (1) HRP20191027T1 (enExample)
HU (1) HUE045300T2 (enExample)
IL (1) IL209864A (enExample)
LT (1) LT2300465T (enExample)
MX (1) MX2010013743A (enExample)
NZ (1) NZ589781A (enExample)
RU (1) RU2518089C2 (enExample)
SI (1) SI2300465T1 (enExample)
WO (1) WO2009150240A1 (enExample)
ZA (1) ZA201008961B (enExample)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101679408B (zh) 2006-12-22 2016-04-27 Astex治疗学有限公司 作为fgfr抑制剂的双环杂环化合物
JP5442449B2 (ja) 2006-12-22 2014-03-12 アステックス、セラピューティックス、リミテッド 新規化合物
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
CA2755285C (en) * 2009-03-20 2014-02-11 Yunxin Y. Bo Inhibitors of pi3 kinase
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
WO2011104731A1 (en) * 2010-02-26 2011-09-01 Decode Genetics Ehf Genetic variants as markers for use in urinary bladder cancer risk assessment, diagnosis, prognosis and treatment
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
EP2727920B1 (en) 2011-07-29 2016-11-02 FUJIFILM Corporation 1,5-naphthyridine derivative or salt thereof
UA111382C2 (uk) 2011-10-10 2016-04-25 Оріон Корпорейшн Інгібітори протеїнкінази
CN103214481B (zh) * 2012-01-21 2016-08-03 中国科学院上海药物研究所 新型咪唑并[1,2-a]吡啶类化合物、其制备方法、包含此类化合物的药物组合物及其用途
CA2876689C (en) 2012-06-13 2022-04-26 Incyte Corporation Substituted tricyclic compounds as fgfr inhibitors
CN102786543B (zh) * 2012-07-24 2016-04-27 上海瑞博化学有限公司 咪唑并[1，2-a]吡啶-6-硼酸频哪醇酯及其衍生物的制备方法
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US8729263B2 (en) 2012-08-13 2014-05-20 Novartis Ag 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
JP6430383B2 (ja) * 2012-09-28 2018-11-28 ヴァンダービルト ユニバーシティーＶａｎｄｅｒｂｉｌｔ Ｕｎｉｖｅｒｓｉｔｙ 選択的ｂｍｐ阻害剤としての縮合複素環化合物
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
MX376108B (es) 2012-12-20 2025-03-07 Tempest Therapeutics Inc Compuestos de triazolona y usos de los mismos.
CN103923078A (zh) * 2013-01-15 2014-07-16 华东理工大学 3,4-二取代(1H-吡唑[3,4-b]吡啶)类化合物及其用途
AR094812A1 (es) 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
US9303043B2 (en) * 2013-03-13 2016-04-05 Greentech, Inc. Process for making benzoxazepin compounds
PH12015502383B1 (en) 2013-04-19 2023-02-03 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
CN105636953B (zh) 2013-07-31 2018-01-02 诺华股份有限公司 1,4‑二取代的哒嗪衍生物及其用于治疗与smn缺乏相关的病症的用途
RU2016129380A (ru) 2013-12-20 2018-01-25 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Замещенные диаминопиримидильные соединения, их композиции и способы лечения с их участием
CN115368356B (zh) * 2013-12-20 2025-05-09 阿斯特克斯治疗有限公司 双环杂环化合物及其治疗用途
WO2016027781A1 (ja) 2014-08-18 2016-02-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 単環ピリジン誘導体の塩およびその結晶
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CA2976790C (en) 2015-02-20 2024-02-27 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
EP4063849B1 (en) * 2015-03-24 2024-01-31 Daicel Corporation Stationary phase for supercritical fluid chromatography
CN114984013A (zh) 2015-03-25 2022-09-02 国立癌症研究中心 胆管癌治疗剂
EP3277704A1 (en) 2015-03-31 2018-02-07 Allergan, Inc. Cyclosporins modified on the mebmt sidechain by heterocyclic rings
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CN116270646A (zh) 2015-10-16 2023-06-23 艾伯维公司 制备咪唑并[1,2-a]吡咯并[2,3-e]吡嗪类化合物及其固态形式的方法
AU2016374441B2 (en) 2015-12-17 2021-10-21 Eisai R&D Management Co., Ltd. Therapeutic agent for breast cancer
WO2018053126A1 (en) * 2016-09-14 2018-03-22 Vanderbilt University Inhibition of bmp signaling, compounds, compositions and uses thereof
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CN109776401A (zh) * 2017-11-14 2019-05-21 成都博腾药业有限公司 一种制备6-氯-5-三氟甲基-2-氨基吡啶的方法
WO2019105886A1 (en) 2017-12-02 2019-06-06 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
WO2019178383A1 (en) 2018-03-14 2019-09-19 Vanderbilt University Inhibition of bmp signaling, compounds, compositions and uses thereof
BR112020017922A2 (pt) 2018-03-28 2020-12-22 Eisai R&D Management Co., Ltd. Agente terapêutico para carcinoma hepatocelular
KR102956194B1 (ko) 2018-05-04 2026-04-23 인사이트 코포레이션 Fgfr 억제제의 염
RS66310B1 (sr) 2018-05-04 2025-01-31 Incyte Corp Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US12378241B2 (en) 2019-07-26 2025-08-05 Cgenetech (Suzhou,China) Co., Ltd. Pyridine derivative as FGFR and VEGFR dual inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
GEP20247679B (en) 2019-10-14 2024-10-10 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US20240158391A1 (en) * 2019-10-15 2024-05-16 Aucentra Therapeutics Pty Ltd Derivatives of 4-(imidazo[1,2-a]pyridin-3-yl)-n-(pyridin-3-yl) pyrimidin-2- amine for treating proliferative diseases and conditions
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CN112851677A (zh) * 2019-11-26 2021-05-28 中国科学院大连化学物理研究所 一种咪唑并吡啶或嘧啶衍生物的合成方法
MX2022006691A (es) 2019-12-04 2022-09-19 Incyte Corp Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr).
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2022161408A1 (zh) * 2021-01-26 2022-08-04 南京明德新药研发有限公司 甲基吡唑取代的吡啶并咪唑类化合物的晶型及其制备方法
EP4323405A1 (en) 2021-04-12 2024-02-21 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
TW202313610A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之三環雜環
CN114047269B (zh) * 2022-01-13 2022-04-15 浙江湃肽生物有限公司南京分公司 一种乙酰基六肽-8的检测方法
CN117659022A (zh) * 2022-09-06 2024-03-08 苏州阿尔脉生物科技有限公司 脲基取代吡啶类化合物、包含其的药物组合物及其医药用途
WO2025038525A1 (en) * 2023-08-11 2025-02-20 Bioventures, Llc Fms-like tyrosine kinase 3 (flt3) inhibitors for treating cell proliferative diseases or conditions
CN117736637B (zh) * 2023-10-18 2024-06-11 山东卓高新材料有限公司 一种自修复防水涂料及其制备方法

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5554630A (en) 1993-03-24 1996-09-10 Neurosearch A/S Benzimidazole compounds
CA2191979A1 (en) 1994-06-20 1995-12-28 Muneo Takatani Condensed imidazole compounds, their production and use
AU5348396A (en) 1995-05-01 1996-11-21 Fujisawa Pharmaceutical Co., Ltd. Imidazo 1,2-a pyridine and imidazo 1,2-a pyridezine derivati ves and their use as bone resorption inhibitors
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
WO1997012613A1 (en) 1995-10-05 1997-04-10 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
TW414795B (en) * 1996-07-01 2000-12-11 Yamanouchi Pharma Co Ltd A thiophene derivative and the pharmaceutical composition
AU747708B2 (en) 1996-07-24 2002-05-23 Du Pont Pharmaceuticals Company Azolo triazines and pyrimidines
CA2744096C (en) 1996-07-31 2013-07-30 Laboratory Corporation Of America Holdings Biomarkers and targets for diagnosis, prognosis and management of prostate disease
CA2291709A1 (en) 1997-05-30 1998-12-03 Merck & Co., Inc. Novel angiogenesis inhibitors
US5990146A (en) 1997-08-20 1999-11-23 Warner-Lambert Company Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation
US6465484B1 (en) 1997-09-26 2002-10-15 Merck & Co., Inc. Angiogenesis inhibitors
IL137019A0 (en) 1998-01-28 2001-06-14 Du Pont Pharm Co Azolo triazines and pyrimidines
CA2341409A1 (en) 1998-08-31 2000-03-09 Merck And Co., Inc. Novel angiogenesis inhibitors
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
EP1206265B1 (en) 1999-06-30 2003-11-12 Merck & Co., Inc. Src kinase inhibitor compounds
US6329380B1 (en) 1999-06-30 2001-12-11 Merck & Co., Inc. SRC kinase inhibitor compounds
WO2001000214A1 (en) 1999-06-30 2001-01-04 Merck & Co., Inc. Src kinase inhibitor compounds
JP2001057292A (ja) 1999-08-20 2001-02-27 Toray Ind Inc 発光素子
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
GB9921150D0 (en) 1999-09-07 1999-11-10 Merck Sharp & Dohme Therapeutic agents
EP1214330A1 (en) 1999-09-21 2002-06-19 LION Bioscience AG Benzimidazole derivatives and combinatorial libraries thereof
GB9927687D0 (en) 1999-11-23 2000-01-19 Merck Sharp & Dohme Therapeutic agents
CA2397661C (en) 2000-03-01 2012-01-03 Janssen Pharmaceutica N.V. 2,4-disubstituted thiazolyl derivatives
MXPA02007603A (es) 2000-03-09 2003-02-24 Aventis Pharma Gmbh Usos terapeuticos de mediadores ppar.
US20020041880A1 (en) 2000-07-05 2002-04-11 Defeo-Jones Deborah Method of treating cancer
JP2004519422A (ja) 2000-08-04 2004-07-02 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー ２−（４−ピリジル）アミノ−６−ジアルコキシフェニルピリド〔２，３−ｄ〕ピリミジン−７−オン
WO2002034748A1 (fr) 2000-10-24 2002-05-02 Sankyo Company, Limited Derives d'imidazopyridine
GB0027561D0 (en) 2000-11-10 2000-12-27 Merck Sharp & Dohme Therapeutic agents
JP2004515496A (ja) 2000-12-07 2004-05-27 アストラゼネカ・アクチエボラーグ ベンズイミダゾール治療剤
US20020107262A1 (en) 2000-12-08 2002-08-08 3M Innovative Properties Company Substituted imidazopyridines
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
SE0100568D0 (sv) 2001-02-20 2001-02-20 Astrazeneca Ab Compounds
SE0100567D0 (sv) 2001-02-20 2001-02-20 Astrazeneca Ab Compounds
BR0207096A (pt) 2001-02-20 2004-01-20 Astrazeneca Ab Uso de um composto, compostos, formulação farmacêutica, e, método de tratamento e/ou profilaxia de condições associadas com a inibição de glicogênio sintase quinase-3
TWI248936B (en) 2001-03-21 2006-02-11 Merck Sharp & Dohme Imidazo-pyrimidine derivatives as ligands for GABA receptors
DE10117183A1 (de) 2001-04-05 2002-10-10 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]-pyridinverbindungen als Arzneimittel
EP2048142A3 (en) 2001-04-26 2009-04-22 Eisai R&D Management Co., Ltd. Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof
AU2002317377A1 (en) 2001-07-20 2003-03-03 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
GB0128499D0 (en) 2001-11-28 2002-01-23 Merck Sharp & Dohme Therapeutic agents
US6900208B2 (en) 2002-03-28 2005-05-31 Bristol Myers Squibb Company Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
CA2483306A1 (en) 2002-04-23 2003-11-06 Shionogi & Co., Ltd. Pyrazolo[1,5-a]pyrimidine derivative and nad(p)h oxidase inhibitor containing the same
JP2004002826A (ja) 2002-04-24 2004-01-08 Sankyo Co Ltd 高分子イミダゾピリジン誘導体
US7125888B2 (en) 2002-05-02 2006-10-24 Merck & Co., Inc. Tyrosine kinase inhibitors
ATE457025T1 (de) 2002-05-23 2010-02-15 Cytopia Res Pty Ltd Kinaseinhibitoren
GB0212049D0 (en) 2002-05-24 2002-07-03 Merck Sharp & Dohme Therapeutic agents
WO2003101993A1 (en) 2002-06-04 2003-12-11 Neogenesis Pharmaceuticals, Inc. Pyrazolo` 1,5a! pyrimidine compounds as antiviral agents
US7196090B2 (en) 2002-07-25 2007-03-27 Warner-Lambert Company Kinase inhibitors
WO2004026867A2 (en) 2002-09-19 2004-04-01 Schering Corporation Imidazopyridines as cyclin dependent kinase inhibitors
GB0223349D0 (en) 2002-10-08 2002-11-13 Merck Sharp & Dohme Therapeutic agents
WO2004035579A1 (ja) 2002-10-15 2004-04-29 Takeda Pharmaceutical Company Limited イミダゾピリジン誘導体、その製造法および用途
AU2003298942A1 (en) 2002-12-11 2004-06-30 Merck And Co., Inc. Tyrosine kinase inhibitors
US7550470B2 (en) 2002-12-11 2009-06-23 Merck & Co. Inc. Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors
US7826979B2 (en) 2003-02-14 2010-11-02 Vertex Pharmaceuticals Incorporated Method of modeling complex formation between a query ligan and a target molecule
US7476670B2 (en) 2003-02-18 2009-01-13 Aventis Pharma S.A. Purine derivatives, method for preparing, pharmaceutical compositions and novel use
US7157460B2 (en) 2003-02-20 2007-01-02 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
WO2004087153A2 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
US7442709B2 (en) 2003-08-21 2008-10-28 Osi Pharmaceuticals, Inc. N3-substituted imidazopyridine c-Kit inhibitors
AP2006003552A0 (en) 2003-08-21 2006-04-30 Osi Pharm Inc N3 - substituted imidazopyridine C-kit inhibitors.
BRPI0413746A (pt) 2003-08-21 2006-10-24 Osi Pharm Inc composto ou um seu n-óxido ou seu sal farmaceuticamente aceitável, composição, e, método de tratamento de distúrbio hiperproliferativo
GB2423083B (en) 2003-12-03 2007-07-11 Cytopia Res Pty Ltd Azole-based kinase inhibitors
JP2007519720A (ja) 2004-01-28 2007-07-19 スミスクライン ビーチャム コーポレーション チアゾール化合物
TW200530236A (en) 2004-02-23 2005-09-16 Chugai Pharmaceutical Co Ltd Heteroaryl phenylurea
US7566781B2 (en) 2004-05-10 2009-07-28 Banyu Pharmaceutical Co., Ltd. Imidazopyridine compound
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
CA2577947A1 (en) 2004-08-31 2006-03-09 Banyu Pharmaceutical Co., Ltd. Novel substituted imidazole derivative
KR20070057965A (ko) 2004-09-21 2007-06-07 신타 파마슈티칼스 코프. 염증 및 면역 관련 용도를 위한 화합물
WO2006038001A1 (en) 2004-10-06 2006-04-13 Celltech R & D Limited Aminopyrimidine derivatives as jnk inhibitors
CA2589770A1 (en) 2004-12-01 2006-06-08 Osi Pharmaceuticals, Inc. N-substituted benzimidazolyl c-kit inhibitors and combinatorial benzimidazole library
JPWO2006070943A1 (ja) 2004-12-28 2008-06-12 武田薬品工業株式会社 縮合イミダゾール化合物およびその用途
EP1836188A1 (en) 2004-12-30 2007-09-26 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
DOP2006000051A (es) * 2005-02-24 2006-08-31 Lilly Co Eli Inhibidores de vegf-r2 y métodos
US7998974B2 (en) 2005-03-03 2011-08-16 Sirtris Pharmaceuticals, Inc. Fused heterocyclic compounds and their use as sirtuin modulators
BRPI0610514A2 (pt) 2005-04-05 2016-11-16 Pharmacopeia Inc composto, composição farmacêutica, e, método de tratamento de um distúrbio
FR2884821B1 (fr) 2005-04-26 2007-07-06 Aventis Pharma Sa Pyrrolopyridines substitues, compositions les contenant, procede de fabrication et utilisation
US7572807B2 (en) 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
AU2006296386A1 (en) 2005-09-30 2007-04-05 Astrazeneca Ab Imidazo [1,2-a] pyridine having anti-cell-proliferation activity
CA2645434A1 (en) 2006-03-20 2007-09-27 Synta Pharmaceutical Corp. Benzoimidazolyl-parazine compounds for inflammation and immune-related uses
AU2007230911A1 (en) 2006-03-23 2007-10-04 Synta Pharmaceuticals Corp. Benzimidazolyl-pyridine compounds for inflammation and immune-related uses
ITVA20060041A1 (it) 2006-07-05 2008-01-06 Dialectica Srl Uso di composti derivati amminotiazolici, di loro composizioni farmaceutiche, nel trattamento di malattie caratterizzate dalla anormale repressione della trascrizione genica, particolarmente il morbo di huntington
TW200811134A (en) 2006-07-12 2008-03-01 Irm Llc Compounds and compositions as protein kinase inhibitors
EP1882475A1 (en) 2006-07-26 2008-01-30 Novartis AG Method of treating disorders mediated by the fibroblast growth factor receptor
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
JP5442449B2 (ja) 2006-12-22 2014-03-12 アステックス、セラピューティックス、リミテッド 新規化合物
CN101679408B (zh) * 2006-12-22 2016-04-27 Astex治疗学有限公司 作为fgfr抑制剂的双环杂环化合物
GB0625826D0 (en) * 2006-12-22 2007-02-07 Astex Therapeutics Ltd New compounds
US8131527B1 (en) 2006-12-22 2012-03-06 Astex Therapeutics Ltd. FGFR pharmacophore compounds
US7977336B2 (en) 2006-12-28 2011-07-12 Banyu Pharmaceutical Co. Ltd Aminopyrimidine derivatives as PLK1 inhibitors
UA101611C2 (ru) 2007-04-03 2013-04-25 Аррей Байофарма Инк. СОЕДИНЕНИЯ ИМИДАЗО[1,2-а]ПИРИДИНА КАК ИНГИБИТОРЫ ТИРОЗИНКИНАЗЫ РЕЦЕПТОРОВ
CA2691987C (en) 2007-06-12 2016-08-16 Achaogen, Inc. Antibacterial agents
WO2009002534A1 (en) 2007-06-26 2008-12-31 Gilead Colorado, Inc. Imidazopyridinyl thiazolyl histone deacetylase inhibitors
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds

Also Published As

Publication number Publication date
LT2300465T (lt) 2019-06-25
BRPI0915084B1 (pt) 2020-02-11
NZ589781A (en) 2013-02-22
KR20110017000A (ko) 2011-02-18
JP2011522866A (ja) 2011-08-04
BRPI0915084B8 (pt) 2021-05-25
IL209864A (en) 2015-10-29
AU2009256584B2 (en) 2014-06-12
JP5596023B2 (ja) 2014-09-24
AU2009256584A1 (en) 2009-12-17
RU2518089C2 (ru) 2014-06-10
KR101745730B1 (ko) 2017-06-12
DK2300465T3 (da) 2019-06-24
WO2009150240A1 (en) 2009-12-17
EP2300465B1 (en) 2019-04-17
CA2727062A1 (en) 2009-12-17
US8796244B2 (en) 2014-08-05
MX2010013743A (es) 2011-02-15
CN102137859A (zh) 2011-07-27
HUE045300T2 (hu) 2019-12-30
CN102137859B (zh) 2015-07-01
US20120208791A1 (en) 2012-08-16
EP2300465A1 (en) 2011-03-30
ES2735979T3 (es) 2019-12-23
SI2300465T1 (sl) 2019-08-30
ZA201008961B (en) 2015-05-27
BRPI0915084A2 (pt) 2015-10-27
IL209864A0 (en) 2011-02-28
HRP20191027T1 (hr) 2019-11-29
RU2011100786A (ru) 2012-07-20

Similar Documents

Publication Publication Date Title
GB0807862D0 (en) Compounds
GB0800035D0 (en) Compounds
GB0804702D0 (en) Compounds
GB0809776D0 (en) Compounds
IL210344A0 (en) New compounds
IL202869A (en) Etinylindole Compounds
GB0807103D0 (en) Compounds
GB0800367D0 (en) Compounds
GB0807910D0 (en) Compounds
HU0800478D0 (en) New compounds
GB0801220D0 (en) Compounds
GB0801265D0 (en) Compounds
GB0810792D0 (en) New compounds
GB0810619D0 (en) Compounds
GB0805993D0 (en) Compounds
GB0807911D0 (en) Compounds
GB0805311D0 (en) Compounds
GB0805048D0 (en) Niovel compounds
GB0800841D0 (en) Compounds
GB0803496D0 (en) Compounds
GB0800454D0 (en) Compounds
GB0802586D0 (en) Compounds
GB0809771D0 (en) Compounds
GB0810118D0 (en) Compounds
GB0803495D0 (en) Compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)